相关实验视频

Updated: Jan 8, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

通过TGF-β1/SMAD3通路,CILP可以减轻肺纤维化

Hua Zou¹, Jiale Dong², Run Zhao²

¹Department of Respiratory Medicine, Affiliated Qingyuan Hospital, Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, 511518, Guangdong, China.

European journal of medical research

|December 11, 2025

概括

软骨中间层蛋白 (CILP) 通过抑制TGF-β1信号传递,有效地对抗异常性肺纤维化 (IPF). 这项研究强调了CILP作为肺纤维化的潜在治疗剂.

科学领域:

肺部医学肺部医学
纤维化研究纤维化研究
分子生物学分子生物学

背景情况:

异形性肺纤维化 (IPF) 是一种进展性肺病,治疗选择有限,以过度纤维组织积累为特征.
转化生长因子-β1 (TGF-β1) 是纤维化的一个关键媒介,但其激活机制尚不清楚.
软骨中间层蛋白 (CILP) 表达在纤维化肺组织中升高,并与TGF-β1.1相互作用.

研究的目的:

研究CILP在肺纤维化中的治疗潜力和潜在机制.
评估CILP对TGF-β1诱导的纤维化反应的作用,在体外和体内.

主要方法:

对人类IPF组织的微阵列分析发现了上调的CILP.
在体外研究中使用了初级小鼠肺纤维细胞,用复合CILP和TGF-β1.1.治疗.
在体内研究中使用了白素 (BLM) 诱导的小鼠模型,用于CILP的肺纤维化.

主要成果:

在纤维细胞中,CILP治疗减弱了TGF-β1诱导的I型原体和α-SMA表达.
CILP抑制了TGF-β1介导的SMAD3酸化和核转位.
在体内,CILP的使用显著降低了BLM治疗小鼠的肺原体沉积,阿什克罗夫特分数和氧含量.

结论:

通过负反机制,CILP可以抑制TGF-β1诱导的肺纤维化.
CILP显示出作为IPF治疗候选药物的潜力,局部作用表明系统风险最小.
进一步研究CILP在肺组织特异性纤维化中的作用是有必要的.

关键词:

这就是CILP的意义.肺部纤维化肺部纤维化在SMAD3中,我们可以看到SMAD3.在TGF-β1中.

更多相关视频

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...